Paul Sorajja, MD

Director, Center for Valve and Structural Heart Disease, Minneapolis Heart Institute, Abbott Northwestern Hospital
Allina Health Minneapolis Heart Institute
Minneapolis, Minnesota, United States

Dr. Sorajja has expertise in valvular and structural heart disease and interventional cardiology. Dr. Sorajja is the national P.I. for multiple clinical trials, including TRILUMINATE, SUMMIT-MAC, EXPAND II, vDyne EFS, and SOAR-EFS. He is highly active in intellectural property development, and has published over 300 manuscripts and book chapters.
 

Disclosure information not submitted.

Presentation(s):

• Restoration of Coaptation with Transcatheter Mitral Repair is not TEER

  Saturday, March 9, 2024
  8:32 AM – 8:40 AM ET

• The Case of TriClip | Summary of the TRILUMINATE Study and FDA Advisory Panel

  Saturday, March 9, 2024
  4:40 PM – 4:50 PM ET

• Panel Discussion | When Repair and When Replacement

  Saturday, March 9, 2024
  5:00 PM – 5:10 PM ET

• Moderated Discussion | Who Should Perform Tricuspid Repair/Replacement and What Will be the Fate of Surgery and Future Technologies for Tricuspid Disease

  Saturday, March 9, 2024
  5:30 PM – 5:40 PM ET

• Anatomy, Indications, and Outcomes for Tricuspid TEER for Incomplete Coaptation

  Sunday, March 10, 2024
  1:38 PM – 1:46 PM ET

• Panel Discussion

  Sunday, March 10, 2024
  2:26 PM – 2:46 PM ET

• Lessons from the TRILUMINATE Pivotal Study Update and Challenges for Commercial Adoption of Transcatheter Tricuspid Repair

  Sunday, March 10, 2024
  3:10 PM – 3:18 PM ET